Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cance...
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
About this item
Full title
Author / Creator
Publisher
England
Journal title
Language
English
Formats
Publication information
Publisher
England
Subjects
More information
Scope and Contents
Contents
About half of patients with papillary thyroid cancer have tumours with activating BRAF(V600E) mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF-positive melanoma, showed clinical benefit in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial. We aimed to establish the activity of vemurafen...
Alternative Titles
Full title
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1817852535
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1817852535
Other Identifiers
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(16)30166-8
